AIM Vaccine’s 13-valent pneumonia conjugate vaccine obtained Production license

AIM Persistence Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the Group, has obtained the requisite drug production license for manufacturing the product. Prior to the outbreak of the COVID-19 pandemic, the product had been the world's top-selling vaccine for ten consecutive years. AIM Vaccine this super heavyweight single product entered the countdown to market.

According to the classification of the World Health Organization, pneumococcal disease is one of the diseases with very high priority use of vaccines for prevention. According to Pfizer's 2023 annual report, Pfizer's global sales of the pneumonia conjugate vaccine in the year of 2023 was approximately USD6,440 million. In addition, the estimated penetration rate of the 13-valent pneumonia conjugate vaccine in the approved age group in China is 25.9%, while the penetration rate in the corresponding age group in the United States exceeds 80%, indicating that there is still significant room for growth in the Chinese market. Domestic sales of the product in 2022 was approximately RMB9,500 million. According to the forecast of China Insights Industry Consultancy Limited, it is expected that the market size of the product will reach RMB35,000 million in 2030.

Based on the estimation of authoritative organizations, the global underserved demand for the 13-valent pneumonia conjugate vaccines is as high as 180 million doses. However, currently, only three companies have been approved to supply them globally. The Group will become an important supplier in the market after the launch of this product, which will significantly enhance the Company's performance.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.